DNLI

Denali Therapeutics Inc.

13 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 22

Positive topline results from Phase 2b LUMA study for Parkinson's treatment.

regulatory action

70%

bearishMay 22

Potential for dilutive equity financing due to high cash burn rates.

capital raise

40%

bullishMay 22

Positive topline results from Phase 2b LUMA study for Parkinson's treatment.

regulatory action

70%

bearishMay 22

Potential for dilutive equity financing due to high cash burn rates.

capital raise

40%

bullishMay 22

Positive topline results from Phase 2b LUMA study for Parkinson's treatment.

regulatory action

70%

bearishMay 22

Potential for dilutive equity financing due to high cash burn rates.

capital raise

40%

bullishMay 22

Positive topline results from Phase 2b LUMA study for Parkinson's treatment.

regulatory action

70%

bearishMay 22

Potential for dilutive equity financing due to high cash burn rates.

capital raise

40%

bullishMay 22

Positive topline results from Phase 2b LUMA study for Parkinson's treatment.

regulatory action

70%

bearishMay 22

Potential for dilutive equity financing due to high cash burn rates.

capital raise

40%

bullishMay 22

Positive topline results from Phase 2b LUMA study for Parkinson's treatment.

regulatory action

70%

bearishMay 22

Potential for dilutive equity financing due to high cash burn rates.

capital raise

40%

neutralMay 7

Takeda terminated collaboration for DNL593, returning full rights to Denali.

management change

30%

bullishMay 7

Received $200 million from synthetic royalty funding agreement following FDA approval.

capital raise

70%

bearishMay 7

G&A expenses increased 14% to support commercial launch without offsetting revenue.

margin compression

60%

bearishMay 7

Continued significant net losses of $128.4 million in Q1 2026.

earnings miss

50%

neutralMay 7

Takeda terminated collaboration for DNL593, returning full rights to Denali.

management change

30%

bullishMay 7

Received $200 million from synthetic royalty funding agreement following FDA approval.

capital raise

70%

bearishMay 7

G&A expenses increased 14% to support commercial launch without offsetting revenue.

margin compression

60%

bearishMay 7

Continued significant net losses of $128.4 million in Q1 2026.

earnings miss

50%

neutralMay 7

Takeda terminated collaboration for DNL593, returning full rights to Denali.

management change

30%

bullishMay 7

Received $200 million from synthetic royalty funding agreement following FDA approval.

capital raise

70%

bearishMay 7

G&A expenses increased 14% to support commercial launch without offsetting revenue.

margin compression

60%

bearishMay 7

Continued significant net losses of $128.4 million in Q1 2026.

earnings miss

50%

neutralMay 7

Takeda terminated collaboration for DNL593, returning full rights to Denali.

management change

30%

bullishMay 7

Received $200 million from synthetic royalty funding agreement following FDA approval.

capital raise

70%

bearishMay 7

G&A expenses increased 14% to support commercial launch without offsetting revenue.

margin compression

60%

bearishMay 7

Continued significant net losses of $128.4 million in Q1 2026.

earnings miss

50%

neutralMay 7

Takeda terminated collaboration for DNL593, returning full rights to Denali.

management change

30%

bullishMay 7

Received $200 million from synthetic royalty funding agreement following FDA approval.

capital raise

70%

bearishMay 7

G&A expenses increased 14% to support commercial launch without offsetting revenue.

margin compression

60%

bearishMay 7

Continued significant net losses of $128.4 million in Q1 2026.

earnings miss

50%

neutralMay 7

Takeda terminated collaboration for DNL593, returning full rights to Denali.

management change

30%

bullishMay 7

Received $200 million from synthetic royalty funding agreement following FDA approval.

capital raise

70%

bearishMay 7

G&A expenses increased 14% to support commercial launch without offsetting revenue.

margin compression

60%

bearishMay 7

Continued significant net losses of $128.4 million in Q1 2026.

earnings miss

50%

neutralMay 7

Takeda terminated collaboration for DNL593, returning full rights to Denali.

management change

30%

bullishMay 7

Received $200 million from synthetic royalty funding agreement following FDA approval.

capital raise

70%

bearishMay 7

G&A expenses increased 14% to support commercial launch without offsetting revenue.

margin compression

60%

bearishMay 7

Continued significant net losses of $128.4 million in Q1 2026.

earnings miss

50%

Filing History

8-KMay 22, 2026

The 8-K filing marks a high-stakes moment for Denali Therapeutics as it reveals the initial outcomes of its Parkinson's program. While the company frames the event as a catalyst for growth, the market must weigh the promise of a breakthrough therapy against the opacity of the topline data and the company's ongoing liquidity needs. The immediate impact hinges on whether subsequent detailed data releases can satisfy investor demands for transparency and clinical efficacy. Ultimately, this filing serves as the primary bridge between Denali's current speculative status and its potential as a commercial-stage biotech leader.

10-QMay 7, 2026

The Q1 2026 filing captures Denali at a high-stakes crossroads: the scientific victory of FDA approval versus the operational challenge of commercialization. The successful launch of AVLAYAH proves the TV platform's viability, but the financial data reveals the steep cost of transitioning from a lab to a pharmacy. The immediate influx of capital from royalty financing provides a necessary bridge, yet it creates a long-term debt-like obligation that will weigh on future profitability. Investors must now weigh the platform's modular potential against the reality of a $130 million quarterly burn. While the recovery of full rights to the DNL593 program following Takeda's exit simplifies the corporate structure, it also removes a cost-sharing partner, increasing the internal funding burden. The overarching impact of the filing is a shift in risk profile from binary clinical trial outcomes to the more complex metrics of commercial execution, market penetration, and reimbursement success.